
~3,800 patients with advanced gastroesophageal junction or gastric adenocarcinoma



Screened for HER2 overexpression with 3+ immunohistochemistry and/or positive fluorescent in-situ hybridization



294 patients: Cisplatin and fluoropyrimidine for 6 cycles, plus trastuzumab every 3 weeks until progession

290 patients: Cisplatin and fluoropyrimidines for 6 cycles